Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tacrolimus therapeutic efficacy in post-liver transplant patients with Cytochrome P450 3A5 (CYP3A5) genetic polymorphisms.

Revista do Colegio Brasileiro de Cirurgioes - 3 Jun 2020

Bezerra Lucas Soares, Santos-Veloso Marcelo Antônio Oliveira, Oliveira Saulo Bruno Lopes de, Dias Anderson André Pantoja, Carvalho-Filho Ângelo Teles de, Gonzaga-Neto Pedro Pereira, Melo Paulo Sérgio Vieira de

Abstract excerpt

Genetic polymorphisms of CYP3A5 have been pointed out as factors that influenciates tacrolimus immunosuppressive efficacy in post liver transplant patients. This study aims to review the literature on the influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphisms of tacrolimus in post-liver transplant patients. This study is a literature review. A combination of the descriptors "tacrolimus", "liver...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP3A
Share to Immunosuppressive Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver Transplantation

Share to Polymorphism, Genetic

Share to Polymorphism, Single Nucleotide

Share to Tacrolimus

Source

Identifiers

PMID: 32578817
DOI: 10.1590/0100-6991e-20202384

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tacrolimus therapeutic efficacy in post-liver transplant patients with Cytochrome P450 3A5 (CYP3A5) genetic polymorphisms.PMID 32578817Read ↗

Association between tacrolimus concentration and genetic polymorphisms of CYP3A5 and ABCB1 during the early stage after liver transplant in an Iranian population.Semantic proximity Read ↗

The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living-donor Egyptian kidney transplanted patients.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing.Semantic proximity Read ↗

Pharmacogenetics of immunosuppressant polymorphism of CYP3A5 in renal transplant recipients.Semantic proximity Read ↗

The pharmacogenetics of Tacrolimus in Algerian kidney recipients' patients.Semantic proximity Read ↗

CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis.Semantic proximity Read ↗

Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations.Semantic proximity Read ↗

Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.Semantic proximity Read ↗

Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver TransplantationSemantic proximity Read ↗

Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.Semantic proximity Read ↗

A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.Semantic proximity Read ↗

Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.